Progression of Cardiovascular Improvement of Different Novel An-tidiabetic Drugs in Patients with Type 2 Diabetes
Type 2 diabetes is an important cause of death from cardiovascular disease.Reasonable glucose control can reduce the risk of cardiovascular disease and improve the prognostic outcomes of cardiovascular disease pa-tients.Traditional hypoglycemic drugs only reduce blood glucose and have less impact on macrovascular complica-tions,while new hypoglycemic drugs have many advantages in the hypoglycemic prognosis of type 2 diabetes pa-tients and have also achieved good clinical results.These drugs include incretin drugs,dipeptidyl peptidase-4 in-hibitors,sodium-glucose cotransporter 2 inhibitors,glucokinase agonists,islet amyloid peptide analogs,etc.This pa-per summarizes the current situation of type 2 diabetes with cardiovascular disease,discusses the cardiovascular protection of different new hypoglycemic drugs in type 2 diabetes patients,and looks forward to the future applica-tiondirection of different new hypoglycemic drugs.
万方数据
维普
